New medical technologies that prolong life result in additional health care use in life years gained. Some of these costs in life years gained are considered to be related to the intervention while other costs are considered unrelated. Here, we argue that ignoring these so-called future medical costs in cost efectiveness analysis is contrary to common sense, results in lost health and fails to inform decision makers for whom cost efectiveness is supposed to serve.

Additional Metadata
Persistent URL
Journal The European Journal of Health Economics
van Baal, P.H.M, Morton, A, Meltzer, D, & Brouwer, W.B.F. (2018). Future unrelated medical costs need to be considered in cost effectiveness analysis. The European Journal of Health Economics, 20, 1–5. Retrieved from